Translate page

Reply: K245N mutation


Your e-mail address will only be available to administators.
X

Topic History of: K245N mutation

Max. showing the last 6 posts - (Last post first)

  • Delphine Rea
  • 's Avatar
1 year 5 months ago
K245N mutation

This mutation is not well know.

Whether asciminib would be efficient is uncertain due to lack of data.

Vodobatinib in trial may also be attempted but again, no set of data against this mutation.

I would not transplant.

I would try to know what is the size of the mutated clone by ngs. I may maintain pona provided stability of mrd ... and change upon increase. Difficult indeed.

Best regards,

Delphine

  • Susanne Saussele
  • 's Avatar
1 year 5 months ago
K245N mutation

Male patient, 50 years old at diagnosis, CML since 11/2019, initial CP, Ph pos, typical transcript, no comorbidities.

Started with nilotinib treatment 11/2019, BCR >1% after 1 Year (3.5%), Dasatinib not tolerated, switch to ponatinib 30mg 1/21 (within a study) increased to 45 mg 6/21 (BCR-ABL 0.5%)

As the BCR::ABL1 level increased in March this year (0.6%) a mutational analysis was performed in 2 labs . One lab detected the K245N mutation.

Since then BCR:ABL1 decreased to 0.2% but is stable for 3 months now, still no MMR.

We recommended an allo SCT as the mutation appeared. But only one donor with mismatch was detected. One son (17 years old) could be a haplo donor.

Patient’s wish is to try asciminib.

What would you do?